基本信息
浏览量:0
职业迁徙
个人简介
Dr. Leong’s mandate is to bring lab-grown ideas to the clinic, with a particular focus on the genitourinary system (kidney, bladder, prostate, testes, urethra, penis). The constant goal is to take concepts developed in the lab and translate them into clinical practice. The group emphasizes multidisciplinary training and collaboration to help trainees become confident and highly skilled scientists.
Dr. Leong is focused on developing “liquid biopsies” that rely on the enumeration of circulating cancer cell fragments, also known as extracellular vesicles, in the blood. Whether they are used to improve early detection for early-stage migration in pancreatic cancer, to avoid overtreatment in breast and prostate cancers, or to improve follow-up and monitoring post-treatment for kidney and colorectal cancers, the goal is to provide a noninvasive companion blood test used in combination with imaging to transform clinical outcomes. We work in collaboration with Drs. Kasia Jerzak, Christopher Lim, Stanley Liu, Laurence Klotz, and Danny Vesprini.
His group also delivers “patient avatars” (patient-derived xenografts) that will help patients select the best therapy during their cancer journey. Their patient-derived xenograft platform allows them to provide pivotal information that will lead to improved response rates in advanced cancer patients. This platform can be used to evaluate chemotherapies, targeted therapies and immunotherapies. We work in collaboration with Drs. Georg Bjarnason, Robert Kerbel, Harvey Wong, and Mark Doherty.
Drug discovery is also a very important research arm, as the group implements various pre-clinical model systems to discover new drugs for various diseases (for example, kidney stones, cancer metastasis, musculoskeletal/cartilage repair).
Dr. Leong is focused on developing “liquid biopsies” that rely on the enumeration of circulating cancer cell fragments, also known as extracellular vesicles, in the blood. Whether they are used to improve early detection for early-stage migration in pancreatic cancer, to avoid overtreatment in breast and prostate cancers, or to improve follow-up and monitoring post-treatment for kidney and colorectal cancers, the goal is to provide a noninvasive companion blood test used in combination with imaging to transform clinical outcomes. We work in collaboration with Drs. Kasia Jerzak, Christopher Lim, Stanley Liu, Laurence Klotz, and Danny Vesprini.
His group also delivers “patient avatars” (patient-derived xenografts) that will help patients select the best therapy during their cancer journey. Their patient-derived xenograft platform allows them to provide pivotal information that will lead to improved response rates in advanced cancer patients. This platform can be used to evaluate chemotherapies, targeted therapies and immunotherapies. We work in collaboration with Drs. Georg Bjarnason, Robert Kerbel, Harvey Wong, and Mark Doherty.
Drug discovery is also a very important research arm, as the group implements various pre-clinical model systems to discover new drugs for various diseases (for example, kidney stones, cancer metastasis, musculoskeletal/cartilage repair).
研究兴趣
论文共 155 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Minzhi Sheng,Gobi Thillainadesan,Amanda Sparkes,Boyang Su, Esther Matus, Jessica Wright,Stanley Liu,Jean Gariepy,Hon S. Leong
Cancer Researchno. 6_Supplement (2024): 61-61
Anjali Balakrishnan,Fermisk Saleh,Lata Adnani,Vorapin Chinchalongporn,Ahmed El-Sehemy,Thomas Olender,Myra J Chen,Shiekh Tanveer Ahmad,Oleksandr Prokopchuk,Lakshmy Vasan,Yacine Touahri,Rehnuma Islam,Sajeevan Sujanthan,Dawn Zinyk,Lacrimioara C Comanita, Boris Kan,Taylor Fleming,Iacovos P Michael,Cindi M Morshead,Hon S Leong,Satoshi Okawa,Marjorie Brand,Valerie A Wallace,Jennifer A Chan,Carol Schuurmans
biorxiv(2024)
Olivia R. Grafinger,Gobi Thillainadesan,Boyang Su,Yulin Mo, Xin Xu,Sara Mar,Minzhi Sheng, Sumaitha Al Islam, Jennifer Geddes-McAllister,Marc G. Coppolino, Hansen H. He, Gang Zheng,Katarzyna J. Jerzak,Hon S. Leong
Cancer Researchno. 6_Supplement (2024): 3203-3203
Theranosticsno. 5 (2024): 1794-1814
Gavin Frame,Hon Leong, Roni Haas,Xiaoyong Huang, Jessica Wright,Paul C. Boutros,Thomas Kislinger,Stanley K. Liu
Cancer Researchno. 6_Supplement (2024): 1274-1274
BRITISH JOURNAL OF CANCER (2024)
Boyang Su,Morteza Jeyhani,Xiaojing Yang,Jina Nanayakkara, Reese Wunsche, Neil Renwich,Scott Tsai,Hon Leong
Cancer Researchno. 6_Supplement (2024): 3624-3624
Trinity Quan,Jessica Cockburn,Sukhbinder Dhesy-Thind,Anita Bane,Hon Leong, Christopher Geleff, Catherine Devion, Noor Ajel,Katarzyna J Jerzak
Current oncologyno. 5 (2024): 2364-2375
Thamara Dayarathna,Austyn D. Roseborough,Janice Gomes,Reza Khazaee, Carolina R. A. Silveira, Kathy Borron, Soojung Yu,Kristy Coleman,Sarah Jesso,Elizabeth Finger,Penny MacDonald,Michael Borrie,Jennie Wells,Robert Bartha, Guangyong Zou,Shawn N. Whitehead,Hon S. Leong,Stephen H. Pasternak
Oncogenepp.1-18, (2024)
加载更多
作者统计
#Papers: 155
#Citation: 2989
H-Index: 34
G-Index: 53
Sociability: 7
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn